 All objectives evaluating DehydraTECH TM drug delivery platform successfully achieved KELOWNA, BC ACCESSWIRE July 22, 2021 Lexaria Bioscience Corp. NASDAQ:LEXXNASDAQ:LEXXW the Company or Lexaria, a global innovator in drug delivery platforms is pleased to review its successful 2021 antiviral drug program to date and summarize expected next steps. Lexarias objectives in its 2021 antiviral drug examination program thus far have been to determine whether: DehydraTECH processing of compounds from leading classes of antiviral drugs for SARS-CoV-2COVID-19, HIVAIDS and other infectious diseases could exhibit evidence of superior oral absorption relative to controls, DehydraTECH processing of those compounds would preserve expected viral inhibitory performance upon efficacy testing in infected mammalian cells, and DehydraTECH does not alter nor degrade the drug molecules chemically as to create new molecular entities that could be challenging to guide through the regulatory approval process. 